Skip to main content

Table 2 Univariate analysis of possible prognostic factors for progression free survival

From: Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors

Variable Hazard ratio (95%CI) P value
Sex
 Female
 Male
1
1.2 (0.8–1.9)
0.46
Diagnosis
 FNA
 FA
1
0.9 (0.5–1.6)
0.64
Age start CTx
  < 60
  ≥ 60
1
1.1 (0.7–1.7)
0.73
Grading
 G1
 G2
1
1.7 (0.98–2.9)
0.058
Ki-67
  ≤ 10 %
  > 10 %
1
1.1 (0.6–2.1)
0.76
Metastases
 Liver only
 Liver and others
1
1.0 (0.7–1.6)
0.91
Response (RECIST)
 No
 Yes
1
0.3 (0.18–0.56)
0.000*
Biochemical response
 No
 Yes
1
0.5 (0.3–0.9)
0.019*
Primary
 Non-pancreatic
 Pancreatic
1
0.8 (0.5–1.4)
0.51
Prior therapy
 No CTx
 CTx
1
0.8 (0.4–1.5)
0.41
Prior therapy
 SSA/IFN
 Others
1
0.9 (0.5–1.4)
0.61
  1. *significant differences; CI confidence interval, FNA functional non active, FA functional active, CTx chemotherapy, SSA somatostatin analogue, IFN interferon